beta-Patchoulene is a tricyclic sesquiterpene hydrocarbon closely associated with patchouli oil chemistry and patchoulol-synthase biosynthesis. Unlike alpha-patchoulene, beta-patchoulene also has a small but direct preclinical literature as an isolated patchouli constituent, with mouse and cell studies reporting anti-inflammatory, antioxidant, metabolic, and cancer-model signals. Those findings are still preclinical only, so AromaForge should frame beta-patchoulene mainly as a patchouli marker constituent with early mechanistic research rather than a clinically established active.
Chemical identity and composition
PubChem lists beta-patchoulene as C15H24. In the local archive, patchouli-dark and related patchouli-dark batch records include beta-patchoulene at about 3%, reinforcing its value as a recurring patchouli fingerprint constituent. Older enzymology and later biosynthesis papers identify beta-patchoulene as one of the hydrocarbon coproducts formed when patchoulol synthase cyclizes farnesyl pyrophosphate.
Aroma and practical use
- Use the recorded woody, earthy, patchouli-like, balsamic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A mouse acute-inflammation study reported dose-dependent inhibition of xylene ear edema, carrageenan paw edema, vascular permeability, pro-inflammatory cytokines, iNOS, COX-2, and NF-kB translocation after beta-patchoulene treatment.
This is the clearest direct isolated-compound anti-inflammatory study located for beta-patchoulene.
This experimental finding does not establish benefit, dose or safety in people using this blend.
An acute lung injury mouse paper found that beta-patchoulene pretreatment lowered mortality-linked injury markers, inflammatory cytokines, MPO, and MDA while suppressing NF-kB and increasing Nrf2/HO-1-related antioxidant signaling.
The study supports a preclinical inflammation-and-oxidative-stress interpretation, not a clinical use claim.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A high-fat-diet and FFA study reported that beta-patchoulene reduced lipid accumulation and improved AMPK-linked lipid metabolism markers in NAFLD models.
The authors used both rat and cell models and found the effect was blunted by an AMPK inhibitor in vitro.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A hepatocellular-carcinoma study reported that beta-patchoulene reduced hypoxia-induced proliferation, migration, invasion, and EMT while promoting apoptosis in liver-cancer models through NF-kB/HIF-1alpha-related signaling changes.
This remains exploratory cancer-model evidence and should not be translated into treatment claims.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA limit, human tolerability trial, or dedicated dermal sensitization dataset for isolated beta-patchoulene was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The strongest public beta-patchoulene literature is pharmacology-oriented and preclinical, so it does not establish safe or effective human use of the isolated compound.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
multiproduct_patchoulol_synthase_cyclization
Patchoulol synthase converts farnesyl pyrophosphate into patchoulol plus several sesquiterpene hydrocarbons, including beta-patchoulene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
nf_kb_suppression_with_downstream_cytokine_reduction
The main inflammation papers link beta-patchoulene to reduced NF-kB activation together with lower TNF-alpha, IL-1beta, IL-6, iNOS, COX-2, and oxidative-stress readouts.
This experimental finding does not establish benefit, dose or safety in people using this blend.
ampk_associated_lipid_metabolism_regulation
A NAFLD paper reported that beta-patchoulene improved hepatic lipid metabolism in association with AMPK pathway activation in rats and L02 cells.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify human clinical evidence for isolated beta-patchoulene.
- Public safety literature for isolated beta-patchoulene is much thinner than the preclinical efficacy literature.
- Most mechanistic claims still depend on animal and cell models rather than translational human data.
- A RIFM peer-reviewed fragrance ingredient safety assessment for beta-Patchoulene (CAS 514-51-2) is indexed at the Fragrance Material Safety Assessment Center, but its full text/details could not be retrieved in this pass, so its specific conclusions are not verified here and are not used to set sensitizing or a numeric dermal limit. sensitizing:true has been corrected to null (unsupported guess) pending confirmed access to that assessment's content.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.